Blog

Dec 19, 2024, 08:08

T790M resistance mutations in EGFR+ lung cancer – EGFR Positive Lung Cancer UK

EGFR Positive Lung Cancer UK shared on X:

“New research offers hope for those with T790M resistance mutations in EGFR+ lung cancer. Scientists have identified CDDO-Me, a compound that shows potential in preclinical studies to stop tumour growth.”

Machine learning-aided discovery of T790M-mutant EGFR inhibitor CDDO-Me effectively suppresses non-small cell lung cancer growth

Authors: Rui Zhou, Ziqian Liu, Tongtong Wu, Xianwei Pan, Tongtong Li, Kaiting Miao, Yuru Li, Xiaohui Hu, Haigang Wu, Andrew M. Hemmings, Beier Jiang, Zhenzhen Zhang, Ning Liu

T790M resistance mutations in EGFR+ lung cancer - EGFR Positive Lung Cancer UK

Andrew M. Hemmings Beier Jiang cancer EGFR Positive Lung Cancer UK Haigang Wu Kaiting Miao Ning Liu OncoDaily Oncology Rui Zhou Tongtong Li Tongtong Wu Xianwei Pan Xiaohui Hu Yuru Li Zhenzhen Zhang Ziqian Liu

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage